UK Markets closed

DBV Technologies S.A. (0QAJ.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
3.5500-0.0970 (-2.66%)
At close: 06:04PM BST
Full screen
Previous close3.6470
Open3.5700
Bid3.4620 x 0
Ask3.6380 x 0
Day's range3.5700 - 3.5740
52-week range2.1916 - 9.8800
Volume1,588
Avg. volume8,584
Market cap195.191M
Beta (5Y monthly)1.59
PE ratio (TTM)N/A
EPS (TTM)-1.9930
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial

    Montrouge, France, September 21, 2022 DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) in the form of a partial clinical hold on its VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical study. In the partial cli

  • Globe Newswire

    DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

    Montrouge, France, September 7, 2022 DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years DBV has finalized the VITESSE protocol after productive exchanges with the U.S. Food and Drug Administration (FDA) concerning key study design elementsDBV expects to screen the first patient in Q4 2022 and anticipates topline results for the VITESSE study to read out in Q1 2025The VITESSE protocol has been sub

  • Globe Newswire

    DBV Technologies to Present at Upcoming Investor Conferences

    Montrouge, France, September 2, 2022 DBV Technologies to Present at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, DBV Technologies, will participate in upcoming investor conferences in September. Wells Fargo Healthcare ConferenceSeptember 7 – 9, 2022 | In-Person Conference | Boston, MADaniel Tassé will be on-site in Boston on T